Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
AstraZeneca
Chinese Patent Office
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim
Deloitte
Dow

Generated: June 25, 2018

DrugPatentWatch Database Preview

SERTRALINE HYDROCHLORIDE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Sertraline Hydrochloride, and when can generic versions of Sertraline Hydrochloride launch?

Sertraline Hydrochloride is a drug marketed by Aci Healthcare Ltd, Aurobindo Pharma, Ranbaxy Labs Ltd, Accord Hlthcare, Actavis Elizabeth, Anda Repository, Apotex Inc, Austarpharma Llc, Chartwell Molecular, Fosun Pharma, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan, Mylan Pharms Inc, Oxford Pharms, Pliva Hrvatska Doo, Sciegen Pharms Inc, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Teva, Torrent Pharms, Watson Labs Teva, Wockhardt, and Zydus Pharms Usa. and is included in twenty-nine NDAs.

The generic ingredient in SERTRALINE HYDROCHLORIDE is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the sertraline hydrochloride profile page.
Drug patent expirations by year for SERTRALINE HYDROCHLORIDE
Pharmacology for SERTRALINE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for SERTRALINE HYDROCHLORIDE
Synonyms for SERTRALINE HYDROCHLORIDE
(+)-cis-(1S,4S)-1-methylamino-4-(3,4-dichlorophenyl)tetralin hydrochloride
(+)-sertraline hydrochloride
(+/-)-Sertraline Hydrochloride
(1 s-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphathalenamine hydrochloride
(1R,4R)-SERTRALINE HCL
(1R,4S)-SERTRALINE HCL
(1s-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphathalenamine hydrochloride
(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride
(1S-cis)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride
(1S,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthyl(methyl)amine hydrochloride
(1S,4S)-[4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL]METHYLAMINE HYDROCHLORIDE
(1S,4S)-1-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-4-(methylamino)naphthalene Hydrochloride
(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride
(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine hydrochloride
(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine hydrochloride
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-aminium chloride
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-tetralin-1-amine hydrochloride
[(1S,4S)-4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YL]-METHYL-AMINE HYDROCHLORIDE
[(1S,4S)-4-(3,4-dichlorophenyl)(1,2,3,4-tetrahydronaphthyl)]methylamine, chlor ide
[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenyl]methylamine hydrochloride
1-NAPHTHALENAMINE, 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-, (1S,4S)-, HYDROCHLORIDE
1-NAPHTHALENAMINE, 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-, HYDROCHLORIDE (1:1), (1S,4S)-
1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride, (1S-cis)-
1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride,(1S-cis)-
1-naphthalenamine,1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-,(1S-cis)-
4- -1,2,3,4-tetrahydro-N-methyl-1-naphthalenaminehydrochloride
559S970
79559-97-0
79617-95-1
79617-96-2 (Parent)
79617-99-5
79951-46-5
AB07662
AC-740
AC1L1Y71
Adjuvin
AK-72966
AKOS005267232
AKOS015846322
AN-15588
AOB2376
Aremis
ARONIS24360
Atruline
BC216562
BLFQGGGGFNSJKA-XHXSRVRCSA-N
BR-72966
C17H17Cl2N.HCl
C17H18Cl3N
CAS-79559-97-0
CCG-39575
CHEBI:9124
CHEMBL1709
Cp 51,974-1
Cp-51,974-1
CP-51974-1
CP-5197401
CP-519741
CPD000466298
CS-2052
CS0024
CTK8E2603
D00825
DSSTox_CID_20243
DSSTox_GSID_40243
DSSTox_RID_79456
DTXSID1040243
EU-0100870
FT-0641726
Gladem
HMS1922P09
HY-B0176A
I14-16426
J10439
KB-205456
KS-00000H1Y
KS-1111
LP00870
LS-94166
LUSTRAL HCL
MCULE-1681469163
MFCD00895772
MLS000758929
MLS001401398
MolPort-003-666-622
NC00198
NC00726
NCGC00092386-01
NCGC00092386-03
NCGC00092386-13
NCGC00261555-01
NE57257
NSC-746308
NSC-758948
NSC746308
NSC758948
Pharmakon1600-01505262
rac-cis-Sertraline Hydrochloride
rac-Sertraline Hydrochloride ((1RS,4RS)-4-(3,4-Dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Hydrochloride)
S0507
S4053
SAM001246666
SAM001247100
SAM002700175
SBB080777
SC-16255
SCHEMBL23230
Serad
Serlift
SERTALINE HYDROCHLORIDE
Sertraline (hydrochloride)
Sertraline for peak identification, European Pharmacopoeia (EP) Reference Standard
Sertraline for system suitability, European Pharmacopoeia (EP) Reference Standard
Sertraline HCl
SERTRALINE HCL FORM I
SERTRALINE HCL FORM II
SERTRALINE HYDRECHLORIDE
Sertraline Hydrochloride (1S-cis)-Isomer
Sertraline hydrochloride (JAN/USAN)
Sertraline hydrochloride [USAN:USP]
Sertraline hydrochloride [USAN]
Sertraline Hydrochloride 1.0 mg/ml in Methanol (as free base)
Sertraline hydrochloride racemic mixture, United States Pharmacopeia (USP) Reference Standard
Sertraline hydrochloride, >=98% (HPLC)
Sertraline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sertraline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sertraline Impurity G HCl
Sertraline.HCl
SMR000466298
SPECTRUM1505262
ST24031612
Tatig
TL8005382
Tox21_111199
Tox21_111199_1
Tox21_500870
TR-031501
Tresleen
UNII-UTI8907Y6X
UTI8907Y6X
Zoloft
Zoloft (TN)
ZOLOFT HCL

US Patents and Regulatory Information for SERTRALINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Torrent Pharms SERTRALINE HYDROCHLORIDE sertraline hydrochloride TABLET;ORAL 077765-001 Feb 6, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin SERTRALINE HYDROCHLORIDE sertraline hydrochloride TABLET;ORAL 077670-002 Feb 6, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hikma Pharms SERTRALINE HYDROCHLORIDE sertraline hydrochloride TABLET;ORAL 077864-002 Aug 10, 2009 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc SERTRALINE HYDROCHLORIDE sertraline hydrochloride TABLET;ORAL 078626-002 Jan 31, 2008 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Julphar
McKesson
QuintilesIMS
Teva
McKinsey
US Army
Baxter
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.